RxDoctor Payments Data

Daniel Reed, MD

Hematology · Charlottesville, VANPI 1578982690

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,990 of the $3,638 with a category attached, or 82.2%. Taiho Oncology, Inc. accounts for 67.7% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $3,394, more than ten times the $201 reported in 2022.

$3,638in general payments, 2019–2025

Across 10 payments — averaging $363.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Taiho Oncology, Inc.$2K
  • Daiichi Sankyo Inc.$650
  • Syndax Pharmaceuticals, Inc.$135
  • Astellas Pharma Global Development$110
  • Incyte Corporation$93
  • Gilead$91
  • plus $96 from 2 others
$2,172in research payments, 2019–2025

Across 1 payment — averaging $2172.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$2K

What the payments were for

  • Consulting fees$2,99082%
  • Food & beverage$55515%
  • Education$933%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,638 in reported general payments places this provider in the 60th percentile of 26 hematology providers in Virginia.

See all hematology providers in Virginia

Medicare billing

Part B allowed, 2024
$45,979
Medicare patients
140
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BesremiRopeginterferon Alfa-2b-Njft11$163,076
InqoviDecitabine/Cedazuridine15$113,311
VenclextaVenetoclax41$100,614
CresembaIsavuconazonium Sulfate11$63,277
Posaconazole27$46,946
Acyclovir56$1,210
Hydroxyurea15$290
Ciprofloxacin Hcl17$223
Ondansetron Hcl24$212
Prochlorperazine Maleate14$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Taiho Oncology, Inc.Inqovi$2,463$113,31115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 26 hematology providers in Virginia.

Other hematology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →